The Brighterside of News on MSN11h
Weight-loss drug Semaglutide could significantly reduce the risk of heart attacks
A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...
Medindia14h
How Bariatric Surgery Offers Hope for Diabetic Kidney Patients
Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients ...
Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to supercharge weight loss for a fraction of the price
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
Snag This Biotech Stock Before November, Here's Why
Charting, Price Performance, News & Related Contracts.
BioWorld17h
FO-4-15, an anti-AD candidate with reduced neurotoxicity and enhanced neuroprotective effects
Researchers from the Chinese Academy of Medical Sciences reported the discovery of the 1,2,4-oxadiazole derivative FO-4-15 for the treatment of Alzheimer’s disease (AD).
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers’ Target?
We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...
How Ozempic Works—and What’s Still a Mystery
Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...